Phathom Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Phathom Pharmaceuticals's estimated annual revenue is currently $14.9M per year.
- Phathom Pharmaceuticals's estimated revenue per employee is $30,554
- Phathom Pharmaceuticals's total funding is $90M.
- Phathom Pharmaceuticals's current valuation is $479.7M. (January 2022)
Employee Data
- Phathom Pharmaceuticals has 487 Employees.
- Phathom Pharmaceuticals grew their employee count by -3% last year.
Phathom Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and President | Reveal Email/Phone |
2 | Co-Founder | Reveal Email/Phone |
3 | Head Information Technology | Reveal Email/Phone |
4 | VP Sales | Reveal Email/Phone |
5 | VP, Financial Planning & Analysis | Reveal Email/Phone |
6 | VP, Regulatory CMC and Clinical Supplies | Reveal Email/Phone |
7 | VP, Head Development Operations | Reveal Email/Phone |
8 | General Counsel | Reveal Email/Phone |
9 | VP, Head Market Access | Reveal Email/Phone |
10 | VP, Head Pharmacovigilance Services and Medical Informatics | Reveal Email/Phone |
Phathom Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Phathom Pharmaceuticals?
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders. We have created a nimble, entrepreneurial environment that fosters the spirit of collective ownership, accountability, proprietorship and achievement ￃﾢ￢ﾂﾬ￢ﾀﾝ elements that are key to our success.
keywords:N/A
$90M
Total Funding
487
Number of Employees
$14.9M
Revenue (est)
-3%
Employee Growth %
$479.7M
Valuation
N/A
Accelerator
Phathom Pharmaceuticals News
At the Needham Healthcare Conference, Phathom Pharmaceuticals Inc. PHAT-0.61%+ Free Alerts. says that licensor Takeda Pharmaceutical Co Ltd.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal...
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal...
Phathom Pharmaceuticals, Inc. reported it has obtained a $200 million term loan facility from Hercules Capital, Inc., a leader in customized debt financing for companies in life sciences and technology-related markets. This additional capital further strengthens Phathoms balance sheet in advanc ...
FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported it has obtained a $200 million term loan f ...
Other Companies in Florham Park
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $103.1M | 513 | 8% | N/A |
#2 | $111.4M | 554 | -7% | N/A |
#3 | $197.2M | 644 | -1% | N/A |
#4 | $181.2M | 809 | 11% | N/A |
#5 | $512.3M | 1458 | -2% | N/A |